Patients | 777 | 756 | 762 |
Age years | 49.2±14.6 | 50.4±13.2 | 48.8±14.0 |
Sex | | | |
Male | 287 (37) | 251 (33) | 285 (37) |
Female | 490 (63) | 505 (67) | 477 (63) |
Ethnicity | | | |
White | 623 (80) | 593 (78) | 597 (78) |
Black or African-American | 28 (4) | 23 (3) | 28 (4) |
Asian | 87 (11) | 95 (13) | 90 (12) |
Other¶ | 39 (5) | 45 (6) | 47 (6) |
BMI+ kg·m−2 | 29.1±6.8 | 29.1±7.0 | 28.6±6.3 |
Eosinophil count+ cells·µL−1 | 375 (0–4494) | 380 (0–3440) | 380 (0–3100) |
Pre-bronchodilator FEV1+ L | 1.71±0.61 | 1.70±0.57 | 1.70±0.60 |
Pre-bronchodilator FEV1+ % pred | 57.0±14.9 | 57.9±14.3 | 56.5±14.6 |
Pre-bronchodilator FEV1/FVC+ % | 61±13 | 61±12 | 60±13 |
Reversibility+ % | 20 (−26–814) | 19 (−24–809) | 21 (−13–171) |
Pre-bronchodilator FVC+ % pred | 75.6 (19.2–122.4) | 76.3 (21.9–125.3) | 76.1 (33.4–143.1) |
Time since asthma diagnosis years | 15.5 (1.1–72.4) | 15.3 (1.1–70.4) | 15.2 (1.1–66.9) |
Age at asthma diagnosis years | 31.6 (0.0–72.4) | 34.6 (0.0–71.1) | 32.0 (0.0–72.0) |
Exacerbations in the past 12 months n | 2.0 (2.0–20.0) | 2.0 (1.0–22.0) | 2.0 (1.0–15.0) |
TASS+ | 2.7±1.1 | 2.7±1.0 | 2.7±1.1 |
ACQ-6 score | 2.8±0.9 | 2.8±0.9 | 2.8±0.9 |
AQLQ(S)+12 score+ | 3.9±1.0 | 4.0±1.0 | 3.9±1.0 |
Nasal polyps | 146 (19) | 136 (18) | 135 (18) |
Atopic | 463 (60) | 444 (59) | 468 (61) |
OCS use | 109 (14) | 90 (12) | 110 (14) |